PUBLIC COMPANY
save$JANXJanux Therapeutics, Inc.
$JANX17.28+1.95%San Diego, CA, USupdated 1d ago
community read0 votes
pipeline
2
marketed
0
phase 3
0
catalysts ytd
1
approvals ytd
0
recalls ytd
0
Pipeline(2)
pipeline depth2 products
2Phase 1
Upcoming
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
- phase1Phase 1 Trial to Study JANX013 and JANX007 Combination in mCRPC
- phase1Study of JANX014 in Subjects With Metastatic Castration-Resistant Prostate Cancer
- EP1Study of JANX011 in Healthy Adult Volunteers to Assess Safety and Tolerability.
- phase1Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)
- phase1Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor Malignancies
🐶 Hiring Signal
next earnings Nov 5, 2026
Where Janux Therapeutics, Inc. is staffing up — a leading indicator of pipeline and commercial priorities.
therapeutic areaOncology 7Immunology & Inflammation 1
News
- BMS CEO Boerner doesn’t ‘feel any compulsion to chase deals’ despite lack of M&A this yearBMS may have been absent from the dealmaking spree of some of its Big Pharma peers this year, but that might not change anytime soon.fiercebiotech · 2mo ago
Data sources
last refreshed 7m ago
Found something off?
comments(0)
5-min edit window · permanent after that